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BACKGROUND: There is no consensus on how to separate contralateral breast cancer (CBC) occurring as distant spread of the primary
breast cancer (BC) from an independent CBC.
METHODS: We used standardised incidence ratios (SIRs) to analyse the variations in the risk of CBC over time among 6629 women
with BC diagnosed between 1954 and 1983. To explore the most appropriate cutoff to separate the two types of CBC, we analysed
the deviance between models including different cutoff points as compared with the basal model with no cutoff date. We also
performed a prognostic study through a Cox model.
RESULTS: The SIR was much higher during the first 2 years of follow-up than afterwards. The best cutoff appeared to be 2 years. The
risk of early CBC was linked to tumour spread and the risk of late CBC was linked to age and to the size of the tumour. Radiotherapy
was not selected by the model either for early or late CBC risk.
CONCLUSION: A clearer pattern of CBC risk might appear if studies used a similar cutoff time after the initial BC.
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The risk of a contralateral breast cancer (CBC) among breast
cancer (BC) survivors has been estimated as two- to six-fold higher
than that of the general population (Parker et al, 1989;
Soerjomataram et al, 2005). However, variations in CBC risk
according to the length of follow-up after the initial BC have not
been clearly documented (Hankey et al, 1983; Brenner et al, 1993;
Soerjomataram et al, 2005; Hooning et al, 2008). One study
assessed variations in CBC risk by 5-year periods, but not by
further details during the first 5 years (Hankey et al, 1983). Others
exclusively analysed risk associated with asynchronous CBC,
considered as a true independent CBC, whereas synchronous
CBC were considered as tumour spread from the primary BC.
Currently, there is no consensus on how to distinguish
independently from synchronous CBC. Indeed, the cutoff time
separating them was arbitrarily chosen, varying widely between 0
and 12 months (Hislop et al, 1984; Basco et al, 1985; Bernstein
et al, 1992; Broe ¨t et al, 1996; Chen et al, 2001; Gao et al, 2003;
Hartman et al, 2005; Howe et al, 2005). The samples studied also
varied because some studies selected only operable BC (Hankey
et al, 1983; Broe ¨t et al, 1996), whereas others analysed populations
selected using many criteria (Chen et al, 2001; Hartman et al, 2005;
Hooning et al, 2008). It is probably for these reasons that the
factors associated with the risk of asynchronous CBC differed
between these studies.
To select the optimal cutoff time for separating independent
from synchronous CBC, and also to identify the CBC risk factors
associated with these categories, we analysed the variations in CBC
risk according to the time elapsed since the first BC in a large
cohort of patients treated between 1954 and 1983.
PATIENTS AND METHODS
The initial cohort included 7711 invasive BC patients treated at the
Institut Gustave-Roussy between 1954 and 1983. We excluded 882
women born abroad because of missing follow-up data, as most of
them returned to their country of origin after treatment, and 200
who did not receive loco-regional treatment because they
presented with distant metastases, or had other severe diseases.
Thus, the study population comprised 6629 patients followed up
until 31 December 2003, of whom only 4% were lost to follow-up;
78% had died by the end of the study. The mean follow-up was 24.7
years (s.e.¼5.6) for the 1061 survivors. When deceased patients
were included (as in Schemper and Smith, 1996), the median
follow-up time was 10.6 years (95% confidence interval (CI):
0.7–21.3). We recorded CBC between the treatment of the first
breast cancer and the first of the following dates: the last medical
visit, death or 31 December 2003.
The analyses were based on the UICC (Union Internationale
Contre le Cancer) TNM classification (UICC, 1974), the presence
(yes/no) of inflammatory breast cancer (IBC), age (both contin-
uous variables and three categories o40, 40–50 and 51 or more),
calendar period (o1963, 1964–1973, 1974 or more), type of
surgery (none, tumorectomy or mastectomy) and radiotherapy
(yes/no). The radiation dose (mainly with Co60 units) most
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ycommonly used was 45Gy in 18 fractions and 30 days, delivered to
the chest wall (or the whole breast after breast-conserving surgery
with a boost dose of 15Gy in six fractions in 10 days, delivered to
the tumour bed). All Nþ patients also received lymph node
radiotherapy to the axilla, supraclavicular area and internal
mammary chain. Patients with N  axillary lymph nodes had not
received lymph node irradiation. Less than 3% of the sample
had received adjuvant chemo- or hormonotherapy, and therefore
these parameters could not be studied. Our data included only four
large tumour types: well-differentiated and undifferentiated
adenocarcinomas, a combination of these two, and a pool of other
histological types, including colloid, lobular and medullary
carcinomas. This information was known for 96% of the patients
who had undergone surgery, but it was not documented for other
patients. All patients were regularly followed up at least every 6
months during the first 5 years and then yearly thereafter.
A systematic annual mammography had been performed since the
late 1950s.
Statistical methods
The risk of CBC was analysed in two steps on the basis of external
and internal comparisons. We compared the incidence of CBC in
our cohort with that of BC in the general population using age-
standardised incidence ratios (SIRs) estimated by Poisson regres-
sion. The reference rates were the national French BC incidence
rates by 5-year age groups for 1975–1995 (Menegoz et al, 1997).
For the periods before 1975 and after 1995, we took into account
the general increase in breast cancer incidence in France, by age
group, using linear regression and applying the regression
coefficient observed in each 5-year period. Poisson regression
was used to test the SIR for departure from unity. The 95% CI were
calculated using maximum likelihood methods. To search for the
most discriminating cutoff point between early and late CBC, we
modelled CBC risk according to the different cutoff times since the
first BC. Each model was nested in the baseline model with no
cutoff, and the difference in deviance was estimated between these
models and the baseline model, which follows a w
2 law with one
degree of freedom; the greater the difference, the better the model
explains the data regarding the change in the CBC risk along the
time axis. We also analysed the relationships between the SIR and
the covariates described above. We used a test of trend or
heterogeneity for each variable and test of interaction between
the SIR observed before and after the cutoff point; all tests were
two-sided.
We performed a prognostic study, using CBC as the end point,
through a Cox model (Cox, 1972), taking into account the cutoff
time previously defined. We first performed a univariate analysis
to select the covariates associated with CBC risk with a P-value of
less than 0.25, which were analysed together in a multivariate
model. We used AKAIKE information criterion to determine the
best final model (Akaike, 1987). All analyses were stratified on the
calendar period of first treatment.
RESULTS
The mean age was 56 years (range: 21–94 years), the largest part of
the population showing a T2 (44%) and 18% a T3 or T4 tumour;
51% of the patients were classified N1, and 18% N2 or N3. Only 9%
of the patients had initial metastases and 10% had IBC; 77%
percent had undergone surgery, mostly a total mastectomy (64%),
and 74% had received loco-regional radiotherapy. We recorded
673 CBCs that had occurred following a median time interval of 3
years with a wide range between 0 and 38 years. The 5-, 10-,
15- and 20-year rates of CBC were 7.1% (95% confidence
interval (CI): 6.5–7.8), 10.5% (95% CI: 9.7–11.4), 12.8% (95%
CI: 11.9–13.9) and 14.7% (95% CI: 13.6–15.9), respectively.
Figure 1 shows the SIR of CBC according to the duration of
follow-up after the diagnosis of the primary BC. Overall, the SIR
was 4.7 (95% CI: 4.3–5.0). The SIR of CBC varied widely according
to the length of the follow-up. Thus, a very high excess risk was
observed during the first 2 years (25 in the first and 10 in the
second year), compared with the general population. After 2 years,
the risk decreased regularly until the 20th year, after which the
CBC risk was not significantly different from that of the general
population.
We found that the greatest difference in deviance between the
basal model and models taking into account the different cutoff
times corresponded to a cutoff time at 2 years of follow-up. This
cutoff was therefore used for all further analyses, which included
275 early CBCs occurring within the first 2 years, and 398 late
CBCs arising at 2 years or more.
The results shown in Table 1 include P-values, first for a test of
trend or heterogeneity for each variable, and second for an
interaction test between the SIR observed before and after 2 years.
All the clinical characteristics of the primary breast cancer were
linked to the risk of CBC for both early and late CBC. As the SIR
was not significantly different between T0, T1 and T2 or between
N0 and N1, these different tumour categories were pooled in the
subsequent analyses. The excess risk for early CBC increased
considerably with tumour extension. For instance, the SIR for
patients with a T4 was 40.8 compared with 73.9 for patients with
N3. For late CBC, similar increases in the SIR were observed, but to
a lesser extent. Thus, the SIR for patients with a T4 was 7.5
compared with 8.6 for patients with N3. The differences between
early and late CBC were clearly different for the N categories (test
for interaction: P¼0.02). An increased SIR was also evidenced for
patients with distant metastases and IBC. No correlation was
observed between any type of histology and the SIR of early and
late CBC (data not shown).
There was clearly a higher risk of CBC for the younger (o40
years) patients for both early and late CBC. However, the risk of
early CBC was 50-fold higher than that of the general population in
the youngest patients, whereas the SIR was only 5-fold higher for
late CBC. After the age of 40 years, the risk of early CBC was also
higher than for late CBC. The interaction test (P¼0.02) confirmed
that the risk of CBC associated with age was different according to
the time elapsed since the first BC (Table 2).
The CBC risks were higher for patients treated before 1973 than
later. They were also much higher for early than for late CBC
(interaction test P¼0.002), because of a higher frequency of
advanced primary tumours during the earliest periods (data not
shown). For this reason, each model was stratified on the calendar
period in the further internal comparison using a Cox model.
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Figure 1 SIR of CBC between 0 and 30 years after the primary breast
cancer.
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radiotherapy had a higher excess risk than the other patients.
However, these parameters were strongly linked to tumour
extension and their independent effect was studied in the
multivariate analysis performed below.
All the variables described in Tables 1 and 2 were taken into
account in the internal analysis, using a Cox model, stratified on
the calendar period. The variables selected in the final models are
shown in Table 3. The risk of early CBC was only associated with
tumour extension and a more aggressive tumour (T, N and IBC).
The risk of late CBC was essentially associated with age and
UICC T. Neither radiotherapy nor surgery remained associated
with the risk of early or late CBC, as the use of these treatments
was strongly dependent on tumour extension. For both early and
late CBC, no significant interaction was found between radio-
therapy and age, even when the model was applied exclusively to
the youngest women (o40 years old), or to 5-year survivors after
the first BC treatment.
When the analyses were restricted to the 3752 breast cancer
patients who had received surgery as the first treatment, similar
results were observed (data not shown). Thus, the risk of early CBC
was linked to a major prognostic factor in this category of patients,
namely the number of involved lymph nodes (0, 1–3, 4–10, 11þ).
The risk of late CBC was only associated with age, and not with any
other tumour extension parameter or type of treatment.
To see whether our results were altered when the cutoff time was
changed, we performed additional analyses, using a cutoff time
first at 6 months and second at 1 year. With these two cutoff times,
we observed that all the factors found to be previously related to
the risk of early CBC (T, N and IBC) were now associated with late
CBC. Age and metastases were also linked to late CBC, whereas the
risk of early CBC was only associated with UICC T.
Five-year survival rates were 38% (35–41%) after a CBC
occurring during the first 2 years, and 56% (53–59%) after a
later CBC. The corresponding 10-year survival rates were 26%
(23–29%) and 42%, respectively (39–45%). Thus, the risk of death
Table 1 Standardised incidence ratios of contralateral breast cancer relative to the French population according to the TNM UICC characteristics of the
primary BC and time elapsed since the first BC
Cases
Characteristics and time since the first BC PYR Observed Expected SIR 95% CI P-value* P-value**
T UICC
o2 years
0 166 3 0.2 12.5 4.0–38.7 o10
 3
1 2108 31 3.0 10.4 7.3–14.7
2 5494 79 7.3 10.8 8.7–13.5
3 2241 61 2.4 25.9 20.1–33.2
4 1577 91 2.3 40.8 33.2–50.1
X2 years 0.18
0 1150 8 2.6 3.1 1.6–6.2 o10
 3
1 15443 88 34.2 2.6 2.1–3.2
2 32825 170 66.8 2.5 2.2–3.0
3 9205 71 16.3 4.4 3.5–5.5
4 2922 45 6.0 7.5 5.6–10.1
N UICC
o2 years
0 4405 67 6.5 10.4 8.2–13.2 o10
 3
1 6173 126 7.5 16.8 14.1–20.0
2 858 48 0.9 54.2 40.8–71.9
3 403 34 0.5 73.9 52.8–103.5
X2 years 0.02
0 27178 156 59.3 2.6 2.2–3.1 o0.01
1 33578 214 65.5 3.3 2.9–3.7
2 2049 20 3.3 6.1 3.9–9.5
3 545 8 0.9 8.6 4.3–17.2
M UICC
o2 years
0 11280 241 14.7 16.4 14.4–18.6 o10
 3
1 560 34 0.7 46.9 33.5–65.6
X2 years 0.6
0 62844 389 128.3 3.0 2.7–3.3 0.02
1 506 9 0.9 10.5 5.4–20.1
Inflammatory BC
o2 years
No 10940 212 14.2 14.9 13.0–17.1 o10
 3
Yes 900 63 1.2 51.5 40.2–65.9
X2 years 0.12
No 61736 375 125.8 3.0 2.7–3.3 o0.01
Yes 1614 23 3.3 6.9 4.6–10.5
Abbreviations: CI¼Confidence interval; PYR¼Number of person-years at risk; SIR¼Standardised Incidence Ratio; UICC¼Union internationale contre le cancer. The SIR is
equal to the ratio between observed and expected cases during the follow-up. *Test of trend for quantitative variables, test of heterogeneity for qualitative variables;
**Interaction test between BC characteristics and the duration of follow-up.
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yafter CBC was 1.4-fold (1.2–1.7) higher for early CBC than for late
CBC (P¼10
 3).
DISCUSSION
In this long-term cohort of 6629 breast cancer patients, we
observed cumulative 10- and 20-year incidence rates of 10.5 and
14.7% for CBC similar to those of most previous reports (Hankey
et al, 1983; Harvey and Brinton, 1985; Bernstein et al, 1992). We
found that CBC risk was almost 5-fold higher than that of primary
BC in the general population. This excess is probably over-
estimated because the systematic clinical and radiological follow-
up of BC patients leads to earlier diagnosis, as in other studies
(Hankey et al, 1983; Parker et al, 1989; Soerjomataram et al, 2005).
The CBC incidence ratios were not constant and varied along the
time axis. They were much higher within the first 2 years after the
first BC than later. After 20 years, the frequency of CBC was not
significantly different from that of the general population.
A similar decreased incidence ratio with the duration of follow-
up has been reported (Obradovic et al, 1988; Schwartz et al, 1989;
Brenner et al, 1993). In other studies, this was only observed in
certain subgroups, such as those with lymph node involvement
(Hankey et al, 1983), or among the youngest women (Hartman
et al, 2005). These variations are probably partly explained by the
selection of the populations studied, which mostly excluded
patients with a high risk of early CBC.
In our study, conducted on an unselected population, we
showed that 2 years was the most appropriate cutoff to separate
CBC occurring as potential tumour spread from the primary BC
from independent CBC. A single cutoff time is probably not the
best model for the variation in overall incidence of CBC over time.
Other more complex models might be considered. However, for a
clinical approach, a single cutoff appears to be the most adequate
way to discriminate the spread dependent on a primary BC from
that on an independent CBC. One of the major limits of this
method is that there is a mixed population of the two types of CBC
around the cutoff point. However, the fact that the risk of death
was very different between early CBC and late CBC indicates that
this cutoff point accurately separates these two distinct entities.
Regarding the initial tumour characteristics (Table 1), both early
and late CBC were associated with more advanced disease,
including IBC, even if a significant interaction was only found
for the clinical N. However, in the multivariate analysis (Table 3),
Table 2 Standardised incidence ratios of contralateral breast cancer according to age at treatment, calendar period of treatment, types of treatment and
time elapsed since the first BC
Cases
Characteristics and time since the first BC PYR Observed Expected SIR 95% CI P-value P-value
Age (years)
o2 years
o40 1138 26 0.5 50.8 34.6–74.6 o10
 3
40–50 3008 74 3.6 20.6 16.4–25.9
450 7694 175 11.2 15.6 13.5–18.1
X2 years 0.02
o40 7076 62 12.0 5.2 4.0–6.6 o10
 3
40–50 21071 119 43.4 2.7 2.3–3.3
450 35203 217 73.7 2.9 2.6–3.4
Calendar period
o2 years
o1963 2289 61 1.6 38.2 29.8–49.3 o10
 3
1963–1973 3377 85 3.9 21.9 17.7–27.1
41973 6174 129 9.8 13.1 11.0–15.6
X2 years 0.002
o1963 12006 69 17.7 3.9 3.1–4.9 0.02
1963–1973 18169 120 35.2 3.4 2.8–4.1
41973 33175 209 76.1 2.7 2.4–3.1
Surgery
o2 years
No surgery 2135 106 2.9 36.0 29.7–43.5 o10
 3
Tumorectomy 1681 22 2.6 8.5 5.6–12.9
Mastectomy 8024 147 9.8 15.0 12.8–17.7
X2 years 0.08
No surgery 4066 49 7.7 6.3 4.8–8.4 o10
 3
Tumorectomy 11393 73 26.3 2.8 2.2–3.5
Mastectomy 47891 276 94.9 2.9 2.6–3.3
Radiotherapy
o2 years
No 3266 47 4.3 11.0 8.3–14.6 o10
 3
Yes 8574 228 11.0 20.7 18.1–23.5
X2 years 0.15
No 23254 116 47.5 2.4 2.0–2.9 0.01
Yes 40096 282 81.5 3.5 3.1–3.9
Abbreviations: CI¼Confidence interval; PYR¼Number of person-years at risk; SIR¼Standardised Incidence Ratio. The SIR is equal to the ratio between observed and
expected cases during the follow-up. *Test of trend for quantitative variables, test of heterogeneity for qualitative variables. **Interaction test between each variable and the
duration of follow-up.
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yearly CBC risk was strongly dependent on tumour extension,
whereas late CBC risk was, apart from age, only associated with
clinical tumour size (T). This last result suggests that at least some
of the early CBC may be part of a generalised metastatic process
and that late CBC comprises two types – independent CBC
associated with age and CBC reflecting later metastatic dissemina-
tion. Similar results were observed in part of our sample, which
included patients treated at the Institut Gustave-Roussy in 1967–
1972 (Fontaine et al, 1986). In an unselected population, patients
with early CBC (occurring 3 months after first BC) had a locally
advanced or metastatic first BC more often than patients with CBC
occurring between 3 and 60 months, or in those with no CBC
(Howe et al, 2005).
Two reports failed to show a relationship between CBC risk and
tumour extension (Bernstein et al, 1992; Broe ¨t et al, 1996), but
chemotherapy was administered to a large proportion of subjects,
which exerted a protective effect on CBC risk. Hence, this might
have cancelled the effect of tumour extension. Our patients
received no chemotherapy, and this may have allowed the natural
history of CBC to be more apparent.
The cutoff point at 2 years contrasts with the commonly
assumed cutoffs of 6 months or less (Bernstein et al, 1992; Broe ¨t
et al, 1996; Chen et al, 2001; Gao et al, 2003; Hartman et al, 2005;
Howe et al, 2005). We therefore repeated our analysis with a cutoff
at 6 months to see whether our results changed. The results
showed that a considerable portion of the previous early CBC
became ‘new’ late CBC. These latter CBC were therefore linked to
the extension of the first BC (TNM, IBC). The ‘new’ early CBC were
only associated with UICC T, suggesting that CBC occurring before
6 months might correspond to the local extension of initially large
tumours rather than a CBC reflecting metastatic dissemination.
In the external analysis, we observed a strong relationship
between an early age and increased risk of CBC, for both early and
late CBC (Table 2). However, when a multivariate analysis was
performed (Table 3), age remained associated with the risk of CBC
only for late CBC, the relationship with risk of early CBC being
entirely explained by more aggressive lesions and tumour spread
occurring in younger patients. Our findings on late CBC risk have
often been reported (Hankey et al, 1983; Kurtz et al, 1988;
Obradovic et al, 1988; Brenner et al, 1993; Broe ¨t et al, 1996;
Mariani et al, 1997; Chen et al, 2001; Hartman et al, 2005;
Mellemkjaer et al, 2006). In a study that did not analyse women
above the age of 54 years such a relationship was not found
(Bernstein et al, 1992). In another study, women aged 56 or more
had a higher risk of CBC than women aged 45–55 years, but a
similar risk to that of the youngest women (o45) (Gao et al, 2003).
Here, however, a cutoff time of 3 months was used, and probably
included many patients with synchronous CBC, which was not
associated with age in this study.
In the external analysis, for both early and late CBC, the risk was
higher during the early years of treatment than during more recent
years, although less so for late CBC (Table 2). As the calendar
periods are strongly associated with tumour extension, the Cox
models were stratified on this parameter. Our study included BC
patients diagnosed during 1954–1983, when the frequency of
locally advanced BC was much higher than it is today. We
therefore verified our results among the operable BC that included
more than 3000 patients. We found that a cutoff time of 2 years
was still valid to discriminate synchronous from independent CBC.
Indeed, we found that the factor most strongly associated with the
risk of early CBC was the number of involved lymph nodes, which
is a major prognostic factor (Chin and Guerra, 1980; Lee and Chan,
1984). The only factor associated with the risk of late CBC was age.
These findings suggest that the cutoff time of 2 years is highly
relevant for separating synchronous CBC, occurring as potential
spread of the primary tumour, from independent CBC, even
among patients with early BC.
Treatment indications are strongly related to initial tumour
extension. For instance, patients with inoperable BC or those
treated with radiotherapy, who had greater tumour extension,
incurred a higher risk of CBC than other patients in the external
analysis (Table 2). However, in the multivariate analysis, neither
the type of surgery nor radiotherapy remained associated with the
risk of CBC. However, our study was not powerful enough to show
a possibly small radiotherapy effect. Only randomised trials on
adjuvant radiotherapy are theoretically able to measure, devoid of
bias, the carcinogenic effect of radiation therapy among women
treated for BC. A recent review of these trials (EBCTCG, 2005a)
showed that the risk of CBC among women with early BC was
slightly higher among the irradiated patients than among the non-
irradiated patients. However, these results merit discussion for two
reasons: first, this excess risk exists only between 5 and 14 years of
follow-up and not later, and second, the risk is higher for older
(after 50 years) than for younger women. After the first few years
of follow-up, a differential quality of follow-up might occur
between the irradiated and non-irradiated women, resulting from
other possible adverse effects of radiotherapy. For instance,
patients with any radiation complication, such as arm lympho-
edema, are more likely to have complete screening, including
mammographies of the contralateral breast, than women without
complications, thus introducing a potential follow-up bias.
Most reports have not shown a relationship between the risk of
CBC and radiotherapy (Basco et al, 1985; Parker et al, 1989;
Bernstein et al, 1992; Broe ¨t et al, 1996; Gao et al, 2003;
Soerjomataram et al, 2005; Hooning et al, 2008), although some
found that the potential risk was higher for the youngest women,
after a long follow-up, and/or for those who had received a higher
radiation dose to the contralateral breast (Boice et al, 1992;
Hooning et al, 2008; Stovall et al, 2008). These results are in
conformity with previous reports on BC risks among women who
received radiotherapy during 1930–1970 for various benign
disorders, in which this decreased markedly with age at radiation
exposure (Shore et al, 1986; Tokunaga et al, 1987; Preston et al,
2002; UNSCEAR, 2008).
Table 3 Prognostic factors for CBC in multivariate analyses using a Cox
model
Time elapsed
since the first BC Risk factors
Number of
events/total
RR
(95% CI) P-value*
o2 years
T UICC
0–2 113/4098 1
a o10
 3
3 61/1312 1.4 (1.0–2.0)
4 101/1219 2.1 (1.5–3.0)
N UICC
0–1 193/5727 1
a o10
 3
2 48/585 1.8 (1.3–2.5)
3 34/317 2.3 (1.5–3.4)
Inflammatory BC
No 212/5995 1
a
Yes 63/634 1.6 (1.2–2.3) o0.01
X2 years
Age in years
o40 68/596 1.4 (1.1–1.8) o0.01
40–50 121/1452 1.0 (0.8–1.2)
450 209/3197 1
a
T UICC
0–2 266/3645 1
a o10
 3
3 71/930 1.4 (1.1–1.8)
4 61/670 2.2 (1.6–2.9)
Abbreviations: CI¼Confidence interval; UICC¼Union internationale contre le cancer;
*Test of trend for quantitative variables, test of heterogeneity for qualitative variables.
aReference category.
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with adjuvant treatments (Bernstein et al, 1992; Broe ¨t et al, 1996;
EBCTCG, 2005b; Bertelsen et al, 2008; Yadav et al, 2008); most
patients in our study did not receive chemotherapy or hormone
therapy.
Our study failed to show any relationship between the tumour
histological type and CBC risk, although our registered data set
was not sufficiently detailed to clarify this further. Numerous
authors found an association between the risk of CBC and lobular
carcinoma (Horn et al, 1987; Horn and Thompson, 1988; Bernstein
et al, 1992; Broe ¨t et al, 1996; Cook et al, 1996), but Hislop et al
(1984), found such a relationship exclusively for early CBC
(occurring within the first year after the first BC), and not for
later CBC. Gao et al (2003), showed a higher risk of CBC in
association with medullary carcinoma. These disparities may
reflect the choice of cutoff time for identifying synchronous and
asynchronous CBC.
In conclusion, CBC is a common disease after a first BC, and
involves a regular clinical and mammographic follow-up.
Early onset of CBC was associated with a worse prognosis, but
clearer patterns of CBC risk might appear if studies used a similar
cutoff time after the first diagnosis. Our study suggests that this
should be at 2 years after first BC diagnosis.
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